# US 2024/0174607 A1 · Psilocybin analogs, salts, compositions, and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174607 A1
- Document ID: US20240174607A1
- Status: Published application
- Kind: A1
- Application number: 18/547,100
- Filed: 2022-03-17
- Published: 2024-05-30
- Earliest claimed: 2021-03-18
- Assignees: Cybin IRL Limited
- Applicants: Cybin IRL Limited
- Inventors: Alex Nivorozhkin; Michael Palfreyman; Pradip Pathare; Kenneth L. Avery; Mohammed Shukoor; James He Huang; Michael E. Morgan; Joan M. Krakowsky
- Web page: https://patentgrep.com/patent/US20240174607A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- C07D 209/16: Tryptamines
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07B 59/002: {Heterocyclic compounds}
- C07C 53/10: Salts thereof
- C07C 53/126: Acids containing more than four carbon atoms
- C07C 55/06: Oxalic acid
- C07C 55/08: Malonic acid
- C07C 55/10: Succinic acid
- C07C 57/03: Monocarboxylic acids
- C07C 57/145: Maleic acid
- C07C 57/15: Fumaric acid
- C07C 59/245: containing hydroxy or O-metal groups
- C07C 59/255: Tartaric acid
- C07C 59/265: Citric acid
- C07C 63/08: Salts thereof
- C07C 65/10: Salicylic acid
- C07C 309/29: of non-condensed six-membered aromatic rings
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.

## Claims

### Claim 1

A crystalline pharmaceutically acceptable salt of a compound of Formula (I), or a stereoisomer, or solvate thereof,
wherein:
R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen or deuterium,
R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
X1 and X2 are deuterium, and
Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein R8 and R9 are —CH3.

### Claim 5 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein R8 and R9 are —CD3.

### Claim at position 5

6-7. (canceled)

### Claim 8 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein Y1 and Y2 are deuterium.

### Claim 9 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein Y1 and Y2 are hydrogen.

### Claim 10 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:

### Claim 11 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein the compound of Formula (I) is

### Claim at position 10

12-17. (canceled)

### Claim 18 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline benzenesulfonate salt of the compound of Formula (I).

### Claim 19 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline benzoate salt of the compound of Formula (I).

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline tartrate salt of the compound of Formula (I).

### Claim 22 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline benzenesulfonate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3a).

### Claim 23 (depends on 22)

The crystalline pharmaceutically acceptable salt of claim 22, wherein the crystalline benzenesulfonate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3a) is characterized by an X-ray powder diffraction pattern containing at least three characteristic peaks at diffraction angles (2θ±0.2°) selected from the group consisting of 7.023°, 7.767°, 11.822°, 12.550°, 12.860°, 13.994°, 15.521°, 18.436°, 19.503°, 20.760°, 21.070°, 22.007°, 22.745°, 23.340°, 24.187°, 25.532°, 26.880°, 27.856°, 28.163°, 31.267°, 33.024°, 35.030°, 36.835°, 39.312°, 40.545°, and 40.988°.

### Claim at position 17

24-25. (canceled)

### Claim 26 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline benzoate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3j).

### Claim 27 (depends on 26)

The crystalline pharmaceutically acceptable salt of claim 26, wherein the crystalline benzoate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3j) is characterized by an X-ray powder diffraction pattern containing at least three characteristic peaks at diffraction angles (2θ+0.2°) selected from the group consisting of 9.486°, 11.006°, 12.379°, 13.428°, 14.608°, 15.446°, 16.389°, 18.247°, 18.977°, 19.346°, 19.831°, 20.868°, 21.447°, 22.860°, 23.878°, 24.944°, 25.737°, 26.144°, 26.341°, 26.990°, 27.708°, 28.595°, 30.048°, 30.763°, 31.127°, 31.839°, 32.800°, 34.460°, 35.444°, 37.725°, and 38.597°.

### Claim at position 20

28-33. (canceled)

### Claim 34 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, which is a crystalline tartrate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3b).

### Claim 35 (depends on 34)

The crystalline pharmaceutically acceptable salt of claim 34, wherein the crystalline tartrate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3b) is characterized by an X-ray powder diffraction pattern containing at least three characteristic peaks at diffraction angles (2θ+0.2°) selected from the group consisting of 6.732°, 12.708°, 13.470°, 14.774°, 15.921°, 16.268°, 17.295°, 18.869°, 20.079°, 20.208°, 20.877°, 21.894°, 22.657°, 23.491°, 23.702°, 24.636°, 24.882°, 25.569°, 26.685°, 27.060°, 27.502°, 28.179°, 28.597°, 29.035°, 29.257°, 29.527°, 31.017°, 31.527°, 32.059°, 32.307°, 33.012°, 34.024°, 34.388°, 34.905°, 35.361°, 36.183°, 37.372°, 37.764°, 38.657°, 41.049°.

### Claim at position 23

36-37. (canceled)

### Claim 38 (depends on 1)

The crystalline pharmaceutically acceptable salt of claim 1, wherein the crystalline pharmaceutically acceptable salt of the compound of Formula (I) has a water solubility from about 1 mg/mL to about 400 mg/mL.

### Claim at position 25

39-85. (canceled)

### Claim 86

A crystalline compound of Formula (I), or a stereoisomer or a solvate thereof,
wherein:
R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen or deuterium,
R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
X1 and X2 are deuterium, and
Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.

### Claim 87 (depends on 86)

The crystalline compound of claim 86, which is crystalline 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3) characterized by an X-ray powder diffraction pattern containing at least three characteristic peaks at diffraction angles (2θ+0.2°) selected from the group consisting of 7.582°, 8.395°, 9.647°, 10.444°, 11.319°, 12.614°, 13.372°, 14.222°, 15.157°, 16.524°, 16.787°, 17.693°, 19.468°, 19.699°, 20.901°, 21.132°, 21.859°, 22.547°, 23.699°, 24.630°, 25.034°, 25.264°, 26.867°, 27.399°, 27.929°, 28.219°, 28.871°, 29.430°, 30.120°, 30.675°, 31.373°, 32.365°, 33.880°, 34.418°, 34.792°, 35.884°, 36.254°, 37.156°, 38.200°, and 38.417°.

### Claim 88 (depends on 86)

The crystalline compound of claim 86, which is crystalline 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3) characterized by an X-ray powder diffraction pattern containing at least three characteristic peaks at diffraction angles (2θ+0.2°) selected from the group consisting of 8.124°, 8.357°, 10.059°, 12.630°, 13.420°, 13.743°, 14.053°, 15.220°, 16.272°, 16.763°, 16.954°, 17.328°, 17.662°, 18.062°, 18.742°, 19.413°, 19.658°, 20.172°, 20.836°, 21.267°, 21.833°, 22.213°, 22.504°, 23.334°, 23.701°, 24.385°, 25.431°, 25.721°, 26.049°, 27.291°, 28.368°, 30.349°, 30.656°, 31.337°, 31.538°, 32.091°, 35.870°, 38.514°, and 41.361°.

### Claim at position 29

89-100. (canceled)

### Claim 101

A citrate salt of a compound of Formula (I), or a stereoisomer, or solvate thereof,
wherein:
R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen or deuterium,
R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
X1 and X2 are deuterium, and
Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.

### Claim 102 (depends on 101)

The citrate salt of claim 101, which is a citrate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (1-3e).

### Claim 103 (depends on 102)

The citrate salt of claim 102, wherein the citrate salt of 3-(2-(bis(methyl-d3)amino)ethyl-1,1,2,2-d4)-1H-indol-4-ol (I-3e) is amorphous by X-ray powder diffraction.
